SCHEMBL6352501

SCHEMBL6352501

COc1cc(O)c2c(=O)oc(CC(=O)O)cc2c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.45
MEN1 O00255 1/20 0.45
SLC22A2 O15244 1/20 0.45
SLC22A1 O15245 1/20 0.45
EED O75530 1/20 0.45
ALOX5 P09917 1/20 0.45
THRB P10828 1/20 0.45
G6PD P11413 1/20 0.45
CBR1 P16152 1/20 0.45
APEX1 P27695 1/20 0.45
BLM P54132 1/20 0.45
KMT2A Q03164 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
MAPT P10636 3/20 0.45
KDM4E B2RXH2 2/20 0.45
ABL1 P00519 1/20 0.45
POLB P06746 1/20 0.45
RIN1 Q13671 1/20 0.45
CTDSP1 Q9GZU7 1/20 0.45
MAOA P21397 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29361626 0.85 MAOA (0.46) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL6345040 0.85 MAOA (0.46) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL6946660 0.83 MAOA (0.45) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL31086523 0.83 MAOA (0.45) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL29769302 0.82 MEN1 (0.42) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL3398957 0.82 MEN1 (0.42) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL6945838 0.80 MAOA (0.42) RECQLMEN1SLC22A2SLC22A1EED
SCHEMBL8051275 0.80 MAOA (0.42) RECQLMEN1SLC22A2SLC22A1EED
Diaporthin SCHEMBL30553770 0.80 MAOA (0.42) RECQLMEN1SLC22A2SLC22A1EED
Diaporthin SCHEMBL29058565 0.80 MAOA (0.42) RECQLMEN1SLC22A2SLC22A1EED

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6900239-B2 Tumor chemopotentiation using isocoumarin derivatives ILWZ ILEX PRODUCTS, INC. (US) 2005-05-31 US disclosed
US-6589981-B2 Combination treatment with ionizing radiation and/or chemotherapy ILEX ONCOLOGY, INC. 2003-07-08 US disclosed
EP-0930310-B1 ISOCOUMARIN DERIVATIVES AND USE THEREOF IN DRUGS MERCIAN CORP (JP) 2003-03-26 EP disclosed
US-20020165210-A1 Tumor chemopotentiation using isocoumarin derivatives GENZYME CORPORATION 2002-11-07 US disclosed
US-20020019366-A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives GLBC LLC 2002-02-14 US disclosed
US-6020363-A IMMUNOLOGY MODERATORS, ANTICANCER AGENTS MERCIAN CORPORATION (JP) 2000-02-01 US disclosed
EP-0930310-A1 ISOCOUMARIN DERIVATIVES AND USE THEREOF IN DRUGS MERCIAN CORPORATION (JP) 1999-07-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019366-A1 Tumor radiosensitization and/or chemopotentiation using isocoumarin derivatives HCCS, IDH2, IDH3A RECQL 1625/4885MEN1 1166/4885SLC22A2 2592/4885
US-20020165210-A1 Tumor chemopotentiation using isocoumarin derivatives MCL1, IDH2, MYADM RECQL 3855/4885MEN1 1491/4885SLC22A2 1095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.